Galcanezumab-gnlm bulk supplier for pharma manufacturers

Galcanezumab-Gnlm 120 mg/mL Suppliers & Bulk Manufacturers

Available Forms: injection (prefilled syringe)

Available Strengths: 120 mg/mL

Reference Brands: Emgality (USA/EU)

Category: Neurology

Galcanezumab-gnlm is a humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP), a molecule involved in migraine attacks. It is used for the prevention of migraine in adults and for the treatment of cluster headaches. Regular monthly injections help reduce migraine frequency and severity.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

Galcanezumab-Gnlm — third party manufacturing & bulk supply

Galcanezumab-Gnlm 120 mg/mL is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Galcanezumab-Gnlm is supplied as injection (prefilled syringe) — an injectable dosage form, so the indicative MOQ is 50,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Galcanezumab-Gnlm listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Galcanezumab-Gnlm →

Back to Listing

Frequently Asked Questions

Galcanezumab-gnlm is listed as injection (prefilled syringe) in 120 mg/mL. Further strengths and pack presentations are confirmed with the manufacturer at RFQ stage.

Galcanezumab-gnlm is referenced against Emgality (USA/EU). Reference brands are shown for identification only and remain the property of their respective trademark owners.